CTOs on the Move

IPS Research Company

www.ipsresearch.com

 
IPS Research Company is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oklahoma City, OK. To find more information about IPS Research Company, please visit www.ipsresearch.com
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.ipsresearch.com
  • 1111 N Lee Ave Ste 400
    Oklahoma City, OK USA 73103-2620
  • Phone: 405.235.8188

Executives

Name Title Contact Details

Similar Companies

A.R.E.B.A. Casriel

A.R.E.B.A. Casriel is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Florida Emergency Physicians

Florida Emergency Physicians is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Maitland, FL. To find more information about Florida Emergency Physicians, please visit www.psrinc.net

Harlan County Health System

Harlan County Health System is a Alma, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifestar Ambulance

Lifestar Ambulance is a Centralia, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.